Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, Di Raimondo F, Borrello I. Romano A, et al. Among authors: forte s. Ann Hematol. 2015 Nov;94(11):1875-83. doi: 10.1007/s00277-015-2462-4. Epub 2015 Jul 31. Ann Hematol. 2015. PMID: 26223359 Free PMC article. Clinical Trial.
Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma.
Romano A, Vetro C, Donnarumma D, Forte S, Ippolito M, Di Raimondo F. Romano A, et al. Among authors: forte s. Haematologica. 2012 Jun;97(6):e21-3; author reply e24. doi: 10.3324/haematol.2012.064576. Haematologica. 2012. PMID: 22665531 Free PMC article. No abstract available.
Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Di Raimondo F. Romano A, et al. Among authors: forte s. Br J Haematol. 2015 Mar;168(5):689-700. doi: 10.1111/bjh.13198. Epub 2014 Nov 7. Br J Haematol. 2015. PMID: 25376846 Free article. Clinical Trial.
Potential Role of Activating Transcription Factor 5 during Osteogenesis.
Vicari L, Calabrese G, Forte S, Giuffrida R, Colarossi C, Parrinello NL, Memeo L. Vicari L, et al. Among authors: forte s. Stem Cells Int. 2016;2016:5282185. doi: 10.1155/2016/5282185. Epub 2015 Dec 6. Stem Cells Int. 2016. PMID: 26770207 Free PMC article.
The Heme Oxygenase System in Hematological Malignancies.
Li Volti G, Tibullo D, Vanella L, Giallongo C, Di Raimondo F, Forte S, Di Rosa M, Signorelli SS, Barbagallo I. Li Volti G, et al. Among authors: forte s. Antioxid Redox Signal. 2017 Aug 20;27(6):363-377. doi: 10.1089/ars.2016.6735. Epub 2017 May 19. Antioxid Redox Signal. 2017. PMID: 28257621 Review.
Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells.
Giallongo C, Tibullo D, Puglisi F, Barbato A, Vicario N, Cambria D, Parrinello NL, Romano A, Conticello C, Forte S, Parenti R, Amorini AM, Lazzarino G, Li Volti G, Palumbo GA, Di Raimondo F. Giallongo C, et al. Among authors: forte s. Cancers (Basel). 2020 Jul 22;12(8):1999. doi: 10.3390/cancers12081999. Cancers (Basel). 2020. PMID: 32707760 Free PMC article.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F. Stella S, et al. Among authors: forte s. Int J Mol Sci. 2019 May 6;20(9):2226. doi: 10.3390/ijms20092226. Int J Mol Sci. 2019. PMID: 31064152 Free PMC article.
215 results